Millions Use Marijuana to Cope with Anxiety and Depression, But a Major New Study Says It …
#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
A comprehensive systematic review challenges the widespread clinical assumption that cannabis effectively treats anxiety and depression, finding insufficient evidence to support its use for these conditions despite millions of patients using it for symptom management. The review’s analysis of existing research indicates that while many patients report subjective improvement, rigorous clinical trials demonstrate limited efficacy and potential risks including paradoxical anxiety exacerbation, particularly with high-THC products. This evidence gap is clinically significant given the prevalence of self-directed cannabis use for mental health and the lack of FDA approval for these indications, highlighting a concerning disconnect between patient perception and empirical evidence. Clinicians should be aware that recommending cannabis for anxiety or depression currently lacks robust evidence support, and patients using cannabis for these purposes should be counseled about limited efficacy data and potential harms. Physicians encountering patients with cannabis-treated anxiety or depression should discuss evidence-based alternatives such as psychotherapy and pharmacotherapy while monitoring for adverse mental health effects if cannabis use continues.
“What we’re seeing clinically is that patients often experience short-term symptom relief with cannabis, but the evidence increasingly suggests this masks underlying anxiety and depression rather than treating them, and over time we observe tolerance, dependence, and worsening mood regulation in many of these individuals.”
? While millions of patients self-report using cannabis for anxiety and depression, emerging evidence suggests the relationship between cannabinoid use and mood disorders is more complex than symptom relief alone. A recent large review challenges the therapeutic efficacy of cannabis for these conditions, though the study’s limitations—including heterogeneity in cannabinoid formulations, dosing regimens, user populations, and outcome measures—warrant careful interpretation before dismissing patient experiences entirely. Clinicians should recognize that perceived symptom improvement may reflect acute anxiolytic effects, placebo response, or self-selection bias rather than sustained clinical benefit, and that regular use may paradoxically worsen anxiety or depression over time in some individuals. When patients with mood disorders present requesting or already using cannabis, a pragmatic approach involves honest discussion about limited evidence for efficacy, potential for dependence, and availability of evidence-based treatments like psychotherapy and pharmacotherapy. Screening for cannabis use in patients with
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Read next
